Aktis Oncology prices upsized US IPO at $18 per share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
- Wall Street posts weekly gains with earnings, inflation data on tap
- Oil prices settle higher as more production shut ahead of hurricane
- Apple cuts iPhone 18 Pro orders due to soft demand, Nikkei Asia reports
- UBS flags level in gold prices where dip buyers will likely emerge
- Telecom stocks tumble on SpaceX spectrum acquisition news
Tweet
Share
E-mail
People exit the New York Stock Exchange (NYSE) on Wall Street in New York City, U.S., January 6, 2026. REUTERS/Brendan McDermid
Jan 8 (Reuters) - Cancer drug developer Aktis Oncology said on Thursday it priced its upsized U.S. initial public offering at $18 per share, raising about $318 million.
Aktis is targeting a valuation of up to $945.4 million in the IPO.
(Reporting by Bipasha Dey in Bengaluru; Editing by Rashmi Aich)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- US stock futures muted as oil stays above $100 ahead of earnings
- Germany's Social Democrats to re-elect full leadership after labour minister's resignation
- In the US, a wealth boom and a price shock collide
Create E-mail Alert Related Categories
ReutersRelated Entities
IPOSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
